FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors


Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12015004537502/12/15Novel compounds
22015000410501/01/15Novel composition
32014037848712/25/14Tricyclic compounds, preparation methods, and their uses
42014037126412/18/14Muscarinic acetylcholine receptor antagonists
52014033508311/13/14Methods of treatment and prevention of eye diseases
62014031197710/23/14Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
72014028813309/25/143 -amino- pyrazole derivatives useful against tuberculosis
82014022725908/14/14Modified proteins and peptides
92014022726408/14/14Drug fusions and conjugates with extended half life
102014020560407/24/14Antigen binding constructs
112014020566107/24/14Formulation for retinoid-containing soft gelatin capsules
122014020021807/17/14Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
132014019340707/10/14Drug fusions and conjugates
142014018775007/03/14Methods for selecting protease resistant polypeptides
152014017971506/26/142,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
162014015870406/12/14Medicament dispenser
172014014099605/22/14Anti-serum albumin biding variable domains
182014011643405/01/14Dry powder inhaler compositions
192014011292904/24/14Tumour necrosis factor receptor 1 antagonists
202014011388804/24/14Novel combination of therapeutic agents
212014011392204/24/14Compounds
222014010589404/17/14Humanized anti-il-18 antibodies
232014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
242014007631403/20/14Manifold for use in medicament dispenser
252014008086303/20/14Muscarinic acetylcholine receptor antagonists
262014005690002/27/14Method for inhibiting binding to b-cell receptor
272014005810502/27/14Substituted diketopiperazines and their use as oxytocin antagonists
282014005071902/20/14Antibodies
292014005172002/20/14N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
302014003898902/06/14Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
312014002359601/23/14Novel composition
322014002455801/23/14Method of treatment
332014000517701/02/14Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
342014000518801/02/14Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
352013034546512/26/13Process for the preparation of retigabine
362013033698912/19/13Methods of identifying a patient population
372013031590111/28/13Novel uses
382013031704111/28/13Compounds
392013031028111/21/13Novel antigen binding proteins
402013030233511/14/13Ligands that bind tgf-beta receptor ii
412013026771710/10/13Process for the preparation of atovaquone
422013026118510/03/13Benzamide derivatives as ep4 receptor agonists
432013025172409/26/13Antigen binding proteins to oncostatin m (osm)
442013025318809/26/13Novel compounds
452013023750109/12/13Benzofuran compounds for the treatment of hepatitis c virus infections
462013022420408/29/13Method of treatment based on atad2 inhibitors
472013021315408/22/13Method of determining cleanliness
482013021339408/22/13Dispensing device
492013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
502013021089208/15/13Method of treatment
512013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
522013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
532013019641208/01/13Magi polynucleotides, polypetides, and antibodies
542013018925507/25/13Fusions and conjugates of insulinotropic agents
552013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
562013011813205/16/13Machine and pharmaceutical and pharmaceutical-like product assembly
572013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
582013010278304/25/13Substituted diketopiperazines and their use as oxytocin antagonists
592013007819803/28/13Novel use
602013005337502/28/13Amino-quinolines as kinase inhibitors
612013003947002/14/13Sample plate for an x-ray powder diffraction apparatus
622013004098402/14/137-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
632013003001201/31/13Compounds
642013003001501/31/13Muscarinic acetylcholine receptor antagonists
652013002354101/24/13Voltage-gated sodium channel blockers
662013001249101/10/13Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
672012031620212/13/12Compounds which have activity at m1 receptor and their uses in medicine
682012030972512/06/12Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
692012030978912/06/12Compounds which have activity at m1 receptor and their uses in medicine
702012028854411/15/12Novel retigabine composition
712012027727911/01/12Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
722012025146810/04/12Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
732012024074209/27/12Novel device
742012024517109/27/12Benzpyrazole derivatives as inhibitors of pi3 kinases
752012023855909/20/12Novel compounds
762012023857109/20/12Indazole derivatives as pi 3-kinase
772012023206109/13/12Novel compounds
782012020774908/16/12Dosing regimen
792012020281108/09/12Novel compounds
802012015744606/21/12Medical use
812012015749106/21/12Muscarinic acetylcholine receptor antagonists
822012015749206/21/12Antibiotic drug
832012014971106/14/12Piperidine derivatives used as orexin antagonists
842012014973106/14/12New medical use
852012012868905/24/12Anti-il-23 immunoglobulins
862012012977805/24/12Ligand that bind tgf-beta receptor rii
872012011464705/10/12Anti-serum album single variable domains
882012010013704/26/12Immunoglobulins
892012010108304/26/12S1p1 agonists comprising a bicyclic n-containing ring
902012010108604/26/12Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
912012010112404/26/121,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
922012010113404/26/125-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
932012010113604/26/125-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
942012006517703/15/12Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
952012005896303/08/12Macrolides with anti-inflammatory activity
962012004625802/23/12Novel crystalline pharmaceutical product
972012004646902/23/12Process for the preparation of a biphenyl-2-yl carbamic acid ester
982012003982002/16/12Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
992012004099102/16/123-azabicyclo [4.1.0] heptanes used as orexin antagonists
1002012004102702/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1012012004102802/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1022012003431202/09/124-isopropyl-3-methylphenol for the treatment of inflammation
1032012000632201/12/12Drug dispenser
1042012000422901/05/12Substituted diketopiperazines and their use as oxytocin antagonists
1052011031937112/29/11Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1062011030569212/15/11Antigen-binding contructs
1072011030569312/15/11Anitigen-binding constructs
1082011028809811/24/11Novel compounds
1092011028190911/17/11Substituted quinoline derivatives as h1 receptor antagonists
1102011027565511/10/11Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1112011027566111/10/11Tricyclic nitrogen compounds used as antibacterials
1122011026973811/03/11Compounds
1132011026997011/03/11Phenethanolamine derivatives for treatment of respiratory diseases
1142011026358810/27/11Tricyclic compounds as glutamate receptor modulators
1152011025375210/20/11Nozzle for a nasal inhaler
1162011025607410/20/11Novel use
1172011024547010/06/11Immunoglobulins
1182011023779209/29/11Quinoline derivatives and their use as 5-ht6 ligands
1192011019027408/04/11Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1202011017806307/21/11Benzpyrazol derivatives as inhibitors of pi3 kinases
1212011016615007/07/11Anhydrous crystal form of ovrepitant maleate
1222011015087106/23/11Treatment of an autoimmune disease using il-18 antagonists
1232011015226206/23/11Novel compounds
1242011014282406/16/11Antibodies against amyloid-beta peptide
1252011014415106/16/11Novel process, salts, composition and use
1262011013569506/09/11Oral dosage form for controlled drug release
1272011013042306/02/11Compounds which have activity at m1 receptor and their uses in medicine
1282011011719005/19/11Pharmaceutical formulations
1292011011826105/19/11Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1302011006164603/17/11Drug dispenser
1312011006474003/17/11Antigen binding proteins
1322011006572503/17/11Triazole amide derivatives for use in therapy
1332011005916703/10/11Encapsulation of biologically active agents
1342011005997903/10/11Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1352011004502702/24/11Adjuvant
1362011004613702/24/11Pyrazole derivatives as p2x7 modulators
1372011003452402/10/11Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1382011002157801/27/11Compounds which potentiate the ampa receptor and uses thereof in medicine
1392011000939401/13/11Tricyclic nitrogen compounds and their use as antibacterial agents
1402011000963101/13/11Phenethanolamine derivatives for treatment of respiratory diseases
1412010032999612/30/10Novel combination of therapeutic agents
1422010032402212/23/10Novel compounds
1432010031657912/16/10Novel use of alkyl phosphate esters
1442010031766612/16/10Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1452010031767212/16/10Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1462010030808212/09/10Dispensing device
1472010031170612/09/10Method of treatment of allergic rhinitis
1482010031173412/09/10Spiro compounds useful as antagonists of the h1 receptor
1492010030382112/02/10Immunoglobulins
1502010030510712/02/10Quinoline derivatives and their use as 5-ht6 ligands
1512010030512712/02/10Novel compounds
1522010030516612/02/10Novel compounds
1532010029222411/18/10Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1542010029229511/18/105-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1552010028615211/11/10N-phenyl hydrazides as modulators of the ghrelin receptor
1562010027590911/04/10Actuator for an inhaler
1572010027385310/28/10Novel isoindol derivatives as ep4 receptor agonists
1582010026769110/21/10Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1592010026773410/21/10N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1602010025619910/07/10Crystalline form of an antimalarial compound
1612010025691910/07/10Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1622010023966609/23/10Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1632010022418509/09/10Actuator for an inhaler
1642010022234909/02/10Quinoline derivatives used to treat inflammatory and allergic diseases
1652010021679908/26/10Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1662010021683708/26/10Glycine transport inhibitors
1672010021067208/19/10Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1682010020325608/12/10Method and the application of powder material to substrates
1692010020424208/12/10Piperazine derivative having affinity for the histamine h3 receptor
1702010020427308/12/10Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1712010019767908/05/10Compounds
1722010019769908/05/10I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1732010019076407/29/10Novel compounds
1742010018477007/22/10Compounds
1752010018499607/22/10Process of amide formation
1762010017569807/15/10Capsule
1772010017406507/08/10Compounds
1782010014809106/17/10Method and system for rapid phase luminescense spectroscopy analysis
1792010015219506/17/10Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1802010014401606/10/10Apparatus for the disruption of animal cells
1812010014475506/10/10Novel compounds
1822010014482906/10/10Novel receptor antagonists and their methods of use
1832010014504006/10/10Benzazepine derivatives for the treatment of neurological disorders
1842010013727606/03/10Compounds which potentiate ampa receptor and uses thereof in medicine
1852010013735306/03/10Tricyclic compounds as antibacterials
1862010013737806/03/10Pyridine compounds for the treatment of prostaglandin mediated diseases
1872010013742806/03/10Oxygen containing heterocycles as glycine transporter inhibiting compounds
1882010013058305/27/10Prolinamide derivatives as modulators of voltage-gated sodium channels
1892010011352105/06/10Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
1902010011352805/06/10Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
1912010011379605/06/10Indole derivatives as s1p1 receptor
1922010010565204/29/10Purines as cysteine protease inhibitors
1932010010568804/29/10Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
1942010010575404/29/105-(4phenyl)prolinamide for treatment of epilepsy
1952010008742404/08/10Tricyclic nitrogen containing heterocycles as antibacterial agents
1962010008750204/08/10Indazoles used to treat estrogen receptor beta mediated disorders
1972010008766704/08/10Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
1982010008183004/01/10Methods of synthesizing n-hydroxysuccinimidyl carbonates
1992010007595303/25/10Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2002010007598203/25/10Pyridinone derivative for the treatment of premature ejaculation
2012010006816603/18/10Oral composition comprising dimethicone copolyol
2022010006940903/18/10"novel compounds"
2032010006941603/18/10Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2042010005905203/11/10Sheet driver for use in a drug dispenser
2052010006309703/11/10Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2062010005650203/04/10Compounds
2072010005652703/04/10Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2082010005659503/04/10Pyrazole derivatives as p2x7 modulators
2092010004863902/25/10Oxadiazole derivates as s1p1 receptor agonists
2102010004167202/18/10Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2112010002969902/04/10Matrix metalloproteinase inhibitors
2122010001628701/21/10Compounds having affinity for dopamine d3 receptor and uses thereof"
2132010001637101/21/10Indole compounds
2142010001002101/14/10Novel compounds
2152010000052801/07/10Manifold for use in medicament dispenser
2162010000052901/07/10Manifold for use in medicament dispenser
2172010000342001/07/10Medicament dispenser
2182010000423001/07/10Azatricyclic compounds and their use
2192010000424001/07/10Indole compounds
2202009032595212/31/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2212009032603212/31/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2222009031849412/24/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2232009031852312/24/09Benzoisoindole derivatives and their use as ep4 receptor agonists
2242009031853012/24/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2252009031238812/17/09Benzo [f] isoindoles as ep4 receptor agonists
2262009031254612/17/09Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2272009030605212/10/09Indenyl derivatives and use thereof for the treatment of neurological disorders
2282009029874212/03/09Process for manufacturing lactose
2292009029114611/26/09Process for manufacturing lactose
2302009029198711/26/09Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester
2312009028676211/19/09Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
2322009027560411/05/09M3 muscarinic acetylcholine receptor antagonists
2332009027035510/29/09Compounds
2342009027051010/29/09Glycine transport inhibitors
2352009025390810/08/09Novel m3 muscarinic acetylchoine receptor antagonists
2362009023644509/24/09Fluid dispenser
2372009023984609/24/09Novel compounds
2382009023284709/17/09Immunogenic compositions
2392009022754709/10/09Novel salt form of a beta2-adrenergic agonist quinolin-2-one derivative
2402009022762909/10/09Compounds having activity at the glycine transporter glyt1 and uses thereof
2412009022157709/03/09Compounds having morpholinyl and piperidinyl groups for use as glyt1 inhibitors
2422009021120108/27/09Apparatus and printing packaging elements
2432009020947208/20/09Amide and peptide derivatives of dialkylenetriamines and their use as transfection agents
2442009020365708/13/09Dual pharmacophores - pde4-muscarinic antagonistics
2452009020367708/13/09Dual pharmacophores - pde4-muscarinic antagonistics
2462009019787108/06/09Dual pharmacophores - pde4-muscarinic antagonistics
2472009019792808/06/09Novel receptor antagonists and their methods of use
2482009018849107/30/09Medicaments
2492009018849207/30/09Canisters for use in metered dose inhalers



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE